You just read:

Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology

News provided by

Halozyme Therapeutics, Inc.

Sep 13, 2019, 01:00 ET